Prosecution Insights
Last updated: April 19, 2026

Imbria Pharmaceuticals Inc.

6 pending office actions

Portfolio Summary

6
Total Pending OAs
3
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
17922890 DOSING METHODS FOR TREATMENT OF CARDIOVASCULAR CONDITIONS FETTEROLF, BRANDON J 1626 Final Rejection Nov 02, 2022
17614826 METHODS OF ALTERING CARDIAC REMODELING USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION NESTOR, DONNA MICHELLE 1627 Non-Final OA Nov 29, 2021
17439763 METHODS OF TREATING CANCER USING TRIMETAZIDINE-BASED COMPOUNDS SCHMIDT, IZABELA MARIA 1621 Non-Final OA Sep 15, 2021
17359714 MODIFIED RELEASE FORMULATIONS OF MODIFIED FORMS OF TRIMETAZIDINE GONZALEZ, LUISALBERTO 1624 Final Rejection Jun 28, 2021
17359726 MODIFIED RELEASE FORMULATIONS OF MODIFIED FORMS OF TRIMETAZIDINE HUI, SAN MING R 1627 Final Rejection Jun 28, 2021
16365074 COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM NEAGU, IRINA 1629 Non-Final OA Mar 26, 2019

Managing Imbria Pharmaceuticals Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month